| Today, Fri, Jul 10, 2009 | | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online (Fri 6:06am)
| | Tue, Jul 7, 2009 | | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online (Tue, Jul 7)
| | | Shire Files Treatment Protocol With FDA Zacks.com (Tue, Jul 7)
| | | Shire moves to head off Genzyme drug shortage for Gacher Disease at bizjournals.com (Tue, Jul 7)
| | | FDA Calendar Updates: Oxford, Protalix, Spectrum, Shire at Seeking Alpha (Tue, Jul 7)
| | Mon, Jul 6, 2009 | | | Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease PR Newswire (Mon, Jul 6)
| | Wed, Jul 1, 2009 | | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online (Wed, Jul 1)
| | | Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment PR Newswire (Wed, Jul 1)
| | Thu, Jun 25, 2009 | | | Ireland's Export Hope at Forbes.com (Thu, Jun 25)
| | Thu, Jun 18, 2009 | | | Your Stocks Just Got Riskier at Motley Fool (Thu, Jun 18)
| | Tue, Jun 16, 2009 | | | FDA urges caution in weighing risks of ADHD drugs AP (Tue, Jun 16)
| | | FDA Cites Limitations of ADHD Drug Study at The Wall Street Journal Online (Tue, Jun 16)
| | Mon, Jun 15, 2009 | | | FDA urges caution in weighing risks of ADHD drugs AP (Mon, Jun 15)
| | | Biotech Stocks: Drug stocks fall sharply; Jazz, AEterna soar at MarketWatch (Mon, Jun 15)
| | | FDA: Kids Shouldn't Stop Taking ADHD Meds at SmartMoney.com (Mon, Jun 15)
| | | FDA: Kids Shouldn't Stop Taking ADHD Meds at SmartMoney.com (Mon, Jun 15)
| | Sat, Jun 13, 2009 | | | [$$] Stocks Reach a Key Inflection Point at Barron's Online (Sat, Jun 13)
| | Wed, Jun 10, 2009 | | | Coverage initiated on Shire Pharm by Sun Trust Rbsn Humphrey Briefing.com (Wed, Jun 10)
| | Mon, Jun 1, 2009 | | | SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits EDGAR Online (Mon, Jun 1)
| | | FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD PR Newswire (Mon, Jun 1)
| Add SHPGY News to My Yahoo!:

| |
|